verified SJR 1,074 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Springer

workspace_premium Q1 — Pharmacology lock_open Open Access

Investigational New Drugs

Investigational New Drugs is a journal indexed in SJR in Pharmacology and Oncology with an H index of 100. It has a price of 3190 €. It has an SJR impact factor of 1,074 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,074.

Investigational New Drugs focuses its scope in these topics and keywords: cancer, acid, solid, tumor, study, phase, patients, mdm, inhibits, growth, ...

ISSN: 0167-6997

Publisher: Springer

Category: Pharmacology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,074 Q1

H-index 100

Acceptance rate pie_chart

25% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.190 € Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,074

H-index

100

Docs (year)

Docs 3y

424

Total refs

2397

Cites 3y

1298

Citable 3y

416

Cites/Doc 2y

2.63

Ref/Doc

31.96

Immediate OA

3190 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Phase I Trial of the Polyamine Analog N1,N14-Diethylhomospermine (DEHSPM) in Patients with Advanced Solid Tumors

Treatment of AIDS Related Non-Hodgkin's Lymphoma with Combination Mitoguazone Dihydrochloride and Low Dose Chop Chemotherapy: Results of a Phase II study

The New Isothiocyanate 4-(Methylthio)Butylisothiocyanate Selectively Affects Cell-Cycle Progression and Apoptosis Induction of Human Leukemia Cells

The Antiangiogenic Agent Neovastat (beta-941) Stimulates Tissue Plasminogen Activator Activity

Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)

Regression of Dalton's lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand

Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers

Phase II Trial of Intra-Arterial Chemotherapy using a Novel Lipophilic Platinum Derivative (SM-11355) in Patients with Hepatocellular Carcinoma

Phase II Study of Interferon Gamma in Malignant Carcinoid Tumors (E9292): A Trial of the Eastern Cooperative Oncology Group

Phase II Study of CI-958 in Patients with Hormone Refractory Prostate Carcinoma

A Novel Combination of Cisplatin, Irinotecan, and Capecitabine in Patients with Advanced Cancer

Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days

SHOW MORE ARTICLES

Pharmacokinetic Drug-Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

Inhibition of Cell Growth, Induction of Apoptosis and Mechanism of Action of the Novel Platinum Compound cis-Diaminechloro-[2-(Diethylamino) Ethyl 4-Amino-Benzoate, N4]-Chloride Platinum (II) Monohydrochloride Monohydrate

Gemcitabine and Cisplatin for Patients with Metastatic or Recurrent Esophageal Carcinoma: A Southwest Oncology Group Study

Emodin induced necroptosis in the glioma cell line U251 via the TNF-a/RIP1/RIP3 pathway

A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

A Phase II Study of 9-Nitro-Camptothecin in Patients with Previously Treated Metastatic Breast Cancer

A Phase I Trial of Daily Oral 4 -N-Benzoyl-Staurosporine in Combination with Protracted Continuous Infusion 5-Fluorouracil in Patients with Advanced Solid Malignancies

FAQs

Investigational New Drugs has an SJR of 1,074 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3190 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Investigational New Drugs is 25%.

Investigational New Drugs

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Investigational New Drugs?

What is the APC / publication cost?

What is the acceptance rate?